Claims
- 1. An isolated nucleic acid sequence coding for a conantokin selected from the group consisting of Conantokin G (Con G) having the amino acid sequence Gly-Glu-Xaa1-Xaa1-Leu-Gin-Xaa2-Asn-Gln-Xaa2-Leu-Ile-Arg-Xaa2-Lys-Ser-Asn (SEQ ID NO: 1), Conantokin T (Con T) having the amino acid sequence Gly-Glu-Xaa1-Xaa1-Tyr-Gln-Lys-Met-Leu-Xaa2-Asn-Leu-Arg-Xaa2-Ala-Glu-Val-Lys-Lys-Asn-Ala (SEQ ID NO:2), Conatokin L (Con L) having the amino acid sequence Gly-Glu-Xaa1-Xaa1-Val-Ala-Lys-Met-Ala-Ala-Xaa2-Leu-Ala-Arg-Xaa2-Asp-Ala-Val-Asn (SEQ ID NO:3), Conantokin R (Con R) having the amino acid sequence Gly-Glu-Xaa1-Xaa1-Val-Ala-Lys-Met-Ala-Ala-Xaa2-Leu-Ala-Arg-Xaa2-Asn-Ile-Ala-Lys-Gly-Cys-Lys-Val-Asn-Cys-Tyr-Pro (SEQ ID NO:4), Conantokin S1 (Con S1) having the amino acid sequence Gly-Asp-Xaa1-Xaa1-Tyr-Ser-Lys-Phe-le-Xaa2-Arg-Glu-Arg-Xaa2-Ala-Gly-Arg-Leu-Asp-Leu-Ser-Lys-Phe-Pro (SEQ ID NO:5), Conantokin Oc (Con Oc) having the amino acid sequence Gly-Glu-Xaa1-Xaa1-Tyr-Arg-Lys-Ala-Met-Ala-Xaa2-Leu-Glu-Ala-Lys-Lys-Ala-Gln-Xaa2-Ala-Leu-Lys-Ala (SEQ ID NO:6), Conantokin Gm (Con Gm) having the amino acid sequence Gly-Ala-Lys-Xaa1-Asp-Arg-Asn-Asn-Ala-Xaa2-Ala-Val-Arg-Xaa2-Arg-Leu-Glu-Glu-Ile (SEQ ID NO:7), Conantokin Ca2 (Con Ca2) having the amino acid sequence Gly-Tyr-Xaa1-Xaa1-Asp-Arg-Xaa2-Ile-Ala-Xaa2-Thr-Val-Arg-Xaa2-Leu-Glu-Glu-Ala (SEQ ID NO:8), Conantokin Qu (Con Qu) having the amino acid sequence Gly-Tyr-Xaa1-Xaa1-Asp-Arg-Xaa2-Val-Ala-Xaa2-Thr-Val-Arg- having the amino acid sequence the formula: Gly-Asn-Asp-Val-Asp-Arg-Lys-Leu-Ala-Xaa2-Leu-Xaa2-Xaa2-Leu-Tyr-Xaa2-Ile (SEQ ID NO:68), wherein Xaa1 γ-carboxyglutamic acid and Xaa2 is selected from the group consisting of γ-carboxyglutamic acid, Ala, Ser, Glu, Tyr and phospo-Ser.
- 2. The isolated nucleic acid of claim 1, wherein Xaa2 is γ-carboxyglutamic acid.
- 3. The isolated nucleic acid of claim 2, wherein said conantokin is selected from the group consisting of Con G, Con R, Con Oc, Con S1, Con L, Con Gm, Con Ca2 and Con Qu.
- 4. The isolated nucleic acid sequence of claim 3 selected from the group consisting of a DNA comprising the nucleotide sequence set forth in SEQ ID NO:45, a DNA comprising the nucleotide sequence set forth in SEQ ID NO:49, a DNA comprising the nucleotide sequence set forth in SEQ ID NO:53, a DNA comprising the nucleotide sequence set forth in SEQ ID NO:55, a DNA comprising the nucleotide sequence set forth in SEQ ID NO:57, a DNA comprising the nucleotide sequence set forth in SEQ ID NO:61, a DNA comprising the nucleotide sequence set forth in SEQ ID NO:63 and a DNA comprising the nucleotide sequence set forth in SEQ ID NO:65.
- 5. A process for identifying nucleic acids encoding conantokins which comprises obtaining a sample containing Conus nucleic acid; subjecting said nucleic acid to amplification using primers selected from the group consisting of an oligonucleotide comprising the DNA sequence set forth in SEQ ID NO:44, an oligonucleotide comprising the DNA sequence set forth in SEQ ID NO:47, an oligonucleotide comprising the DNA sequence set forth in SEQ ID NO:48, an oligonucleotide comprising the DNA sequence set forth in SEQ ID NO:51, an oligonucleotide comprising the DNA sequence set forth in SEQ ID NO:59, and an oligonucleotide which is complimentary to a DNA sequence encoding the peptide comprising the amino acid sequence set forth in SEQ ID NO:67 to form amplification products; and identifying said amplification products.
- 6. An oligonucleotide primer selected from the group consisting of oligonucleotide comprising the DNA sequence set forth in SEQ ID NO:44, an oligonucleotide comprising the DNA sequence set forth in SEQ ID NO:47, an oligonucleotide comprising the DNA sequence set forth in SEQ ID NO:48, an oligonucleotide comprising the DNA sequence set forth in SEQ ID NO:51, an oligonucleotide comprising the DNA sequence set forth in SEQ ID NO:59, and an oligonucleotide which is complimentary to a DNA sequence encoding the peptide comprising the amino acid sequence set forth in SEQ ID NO:67.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application is a division of U.S. patent application Ser. No. 09/142,080 filed May 15, 2000, now U.S. Pat. No. 6,515,103, which is a national stage filing under 35 U.S.C. §371 of PCT/US97/12618, filed on Jul. 21, 1997, which in turn is a continuation-in-part of U.S. patent application Ser. No. 08/684,742 filed Jul. 22, 1996.
Government Interests
[0002] This invention was made with Government support under Grant No. PO1 GM48677 awarded by the National Institute of General Medical Sciences, National Institutes of Health, Bethesda, Md. The United States Government has certain rights in the invention.
Divisions (1)
|
Number |
Date |
Country |
Parent |
09142080 |
May 2000 |
US |
Child |
10357467 |
Feb 2003 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
08684742 |
Jul 1996 |
US |
Child |
PCT/US97/12618 |
Jul 1997 |
US |